D-Cycloserine and Psychedelic Tryptamine Combination for Neural Pathway Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic human afflictions using psychedelic compounds often require full psychedelic doses, which can be time-consuming, resource-intensive, and unpredictable, and may exacerbate conditions like depression and PTSD, while low-dose administration lacks clinical evidence for efficacy.
Innovation Solution
Administering a psychedelic tryptamine at sub-hallucinogenic doses in combination with D-cycloserine on a pulsed basis to modify neural pathways, increasing NMDA receptor transmission and promoting neuroplasticity, thereby providing therapeutic benefits without the side effects of full psychedelic trips.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full psychedelic doses are administered to achieve therapeutic benefits, then treatment efficacy is improved, but treatment complexity and resource requirements increase significantly
Solution Approach 1:
The treatment is segmented into two distinct components: (1) administration of sub-hallucinogenic psychedelic compound, and (2) administration of D-cycloserine. This segmentation allows each component to contribute differently to the therapeutic effect, reducing the complexity associated with full-dose psychedelic monitoring while maintaining treatment efficacy.
Solution Approach 2:
D-cycloserine acts as an intermediary substance that enhances the therapeutic effects of sub-hallucinogenic psychedelic doses. By introducing this mediator, the patent achieves full therapeutic benefits without requiring the complex monitoring and resource allocation needed for high-dose psychedelic administration alone.
2Reliability
If full psychedelic doses are administered to ensure therapeutic effectiveness, then treatment outcomes are improved, but time consumption and resource investment increase
Solution Approach 1:
D-cycloserine is administered in advance or concurrently with the sub-hallucinogenic psychedelic dose to pre-condition the neural pathways. This preliminary action enhances the effectiveness of the reduced psychedelic dose, eliminating the need for extended monitoring periods typically required after full-dose psychedelic administration.
Solution Approach 2:
The patent employs pulsed administration schedules where sub-hallucinogenic psychedelic compounds and D-cycloserine are given on specific days (e.g., Monday, Wednesday, Friday) rather than daily. This periodic approach maintains treatment effectiveness while significantly reducing total time consumption and resource investment compared to continuous full-dose regimens.
3Reliability
If full psychedelic doses are used to achieve therapeutic benefits, then treatment efficacy is improved, but adverse effects and unpredictability increase
Solution Approach 1:
The patent uses partial action by administering sub-hallucinogenic doses of psychedelic compounds (below the threshold for full psychedelic effects) combined with D-cycloserine. This partial dosing strategy achieves sufficient therapeutic benefit while avoiding the adverse effects and unpredictability associated with full psychedelic trips, including exacerbation of depression and PTSD symptoms.
Solution Approach 2:
D-cycloserine, which at high doses can have psychotomimetic side effects, is used at low doses (75 mg or lower) where it acts as an NMDA receptor partial agonist to enhance glutamatergic transmission. This converts a potentially harmful substance into a beneficial adjunct that amplifies the therapeutic effects of sub-hallucinogenic psychedelic doses while minimizing adverse reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the magnitude and duration of therapeutic benefits, simplifies administration, reduces side effects, and improves treatment outcomes for anxiety disorders, depression, dementia, and other chronic conditions, while avoiding the need for extended monitoring and reducing the risk of adverse reactions.
Implementation Method 1
At low doses (75 mg or lower), the NMDA receptor partial agonist DCS typically increases NMDA receptor transmission
Implementation Method 2
These psychedelic agents are serotonin receptor agonists, generally with significant activity at serotonin 5-HT2A receptors
Data Source
AI summary
Methods and pharmaceutical compositions are described for treating a variety of chronic human afflictions including anxiety disorders, eating disorders, chronic pain, depression, addictive disorders, dementia (e.g., Alzheimer's disease, frontotemporal dementia, Lewy body disorder, and vascular dementia), traumatic brain injury (TBI) and mild cognitive impairment. A sub-hallucinogenic dose of a psychedelic tryptamine, including for example psilacetin and psilocybin, along with a low dose of D-cycloserine are administered to human subjects in order to modify neural pathways to treat the chronic affliction.